CK0803 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05695521 (ClinicalTrials.gov) | January 30, 2023 | 3/1/2023 | Regulatory T Cells for Amyotrophic Lateral Sclerosis | Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial | Amyotrophic Lateral Sclerosis | Biological: CK0803;Other: Excipient | Cellenkos, Inc. | NULL | Not yet recruiting | 18 Years | 95 Years | All | 66 | Phase 1 | United States |